Comparison · NCT01227278-sae
Benralizumab 100 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Benralizumab 100 mg vs Placebo: serious adverse events. Trial comparisons, record NCT01227278-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01227278-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.275 | 0.171 | 0.409 | wilson | |
| Risk in group 2 | 0.18 | 0.0977 | 0.308 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0945 | -0.07 | 0.253 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.53 | 0.727 | 3.2 | log | |
| Odds ratio, group 1 over group 2 | 1.72 | 0.668 | 4.45 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Benralizumab 100 mg than on Placebo | 10.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Benralizumab 100 mg | Benralizumab (MEDI-563) 100 milligram (mg) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337). | 14 | 51 | EG001 |
| Group 2 | Placebo | Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337). | 9 | 50 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 to 561
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- NCT number
- NCT01227278
- Phases
- PHASE2
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo, Benralizumab 100 mg
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2016-10-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01227278?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01227278-sae